Kaynaklar

• D'Arcy PF, Griffin JP. Talidomide revisited. Adverse Drug React Toxicol Rev 1994; 13(2): 65–76.
   Google Scholar
• Doris IS. Pharmacovigilance: What to do if you see an adverse reaction and the consequences. Eur J Radiol 2008; 66(2): 184–6.
   Web of Science ®Google Scholar
• Akici A, Oktay Ş. Rational Pharmacotherapy and Pharmacovigilance. Current Drug Safety 2007; 2(1): 65–9.
   Google Scholar
• Beijer HJM, De Blaey CJ. Hospitalisations caused by adverse drug reactions: a meta-analysis of observational studies. Pharm World Sci 2002; 24(2): 46–54.
   PubMed Web of Science ®Google Scholar
• Jose J, Rao PG. Pattern of adverse drug reactions notified by spontaneous reporting in an Indian tertiary care teaching hospital. Pharmacol Res 2006; 54(3): 226–33.
   PubMed Web of Science ®Google Scholar
• Lazarou J, Pomeranz BH, Corey PN. Incidence of advese drug reactions in hospitalized patients: a meta-analysis of prospective studies. JAMA 1998; 279(15): 1200–5.
   PubMed Web of Science ®Google Scholar
• Pirmohamed M, Breckenride AM, Kitteringham NR, Park BK. Adverse drug reactions. Brit Med J 1998; 316(7140): 1295–8.
   PubMedGoogle Scholar
• Classen DC, Pestotnik SL, Evans RS, Lloyd JF, Burke JP. Adverse drug events in hospitalized patients. Excess length of stay, extra costs, and attributable mortality. J Am Med Assoc 1997; 277(4): 301–6.
   Google Scholar
• Lauria-Horner B, Pohl R. Pregabalin: a new anxiolytic. Expert Opin Investig Drugs 2003; 12(4): 663–72.
   PubMed Web of Science ®Google Scholar
• Field M, Oles R, Lewis A, McCleary S, Hughes J, Singh L. Gabapentin (neurontin) and S-3-isobutylgaba represent a novel class of selective antihyperalgesic agents. Br J Pharmacol 1997; 121(8): 1513–22.
   PubMed Web of Science ®Google Scholar
• Feng M, Turluck D, Burleigh J, Lister R, Fan C, Middlebrook A, et al. Brain microdialysis and PK/PD correlation of pregabalin in rats. Eur J Drug Metab Pharmacokinet 2001; 26(1–2): 123–8.
   PubMed Web of Science ®Google Scholar
• Partridge B, Chaplan S, Sakamoto E, Yaksh T. Characterization of the effects of gabapentin and 3-isobutyl-aminobutyric acid on substance P-induced thermal hyperalgesia. Anesthesiology 1998; 88(1): 196–205.
   Web of Science ®Google Scholar
• Jun J, Yaksh T. The effect of intrathecal gabapentin and 3-isobutyl y-aminobutyric acid on the hyperalgesia observed after thermal injury in the rat. Anesth Analg 1998; 86(2): 348–54.
   Web of Science ®Google Scholar
• Yargic I, Ozdemiroglu FA. Pregabalin kötüye kullanımı: bir olgu sunumu. Klinik Psikofarmakoloji Bülteni—Bulletin of Clinical Psychopharmacology 2011; 21(1): 64–6.
   Web of Science ®Google Scholar
• Pande AC, Crockatt JG, Feltner DE, Janney CA, Smith WT, Weisler R, et al. Pregabalin in generalized anxiety disorder: a placebo controlled trial. Am J Psychiatry 2003; 160(3): 533–40.
   PubMed Web of Science ®Google Scholar
• Gee NS, Brown JP, Dissanayake VU, Offord J, Thurlow R, Woodruff GN. The novel anticonvulsant drug, gabapentin (Neurontin), binds to the α2-δ subunit of a calcium channel. J Biol Chem 1996; 271(10): 5768–76.
   PubMed Web of Science ®Google Scholar
• Fink K, Dooley DJ, Meder WP, Suman-Chauhan N, Duffy S, Clusmann H, et al. Inhibition of neuronal Ca2+ influx by gabapentin and pregabalin in the human neocortex. Neuropharmacology 2002; 42(2): 229–36.
   PubMed Web of Science ®Google Scholar
• Dooley DJ, Mieske CA, Borosky SA. Inhibition of K+-evoked glutamate release from rat neocortical and hippocampal slices by gabapentin. Neurosci Lett 2000; 280(2): 107–10.
   PubMed Web of Science ®Google Scholar
• Dooley DJ, Donovan CM, Pugsley TA. Stimulus-dependent nodulation of [3H]norepinephrine release from rat neocortical slices by gabapentin and pregabalin. J Pharmacol Exp Ther 2000; 295(3): 1086–93.
   PubMed Web of Science ®Google Scholar
• Maneuf YP, Hughes J, McKnight AT. Gabapentin inhibits the substance P-facilitated K+-evoked release of [3H]glutamate from rat caudal trigeminal nucleus slices. Pain 2001; 93(2): 191–6.
   PubMed Web of Science ®Google Scholar
• Jones D, Sorkin L. Systemic gabapentin and (S-[+]-3-isobutyl-_- aminobutyric acid block secondary hyperalgesia. Brain Res 1998 (1–2); 810: 93–9.
   PubMed Web of Science ®Google Scholar
• Bialer M, Johannessen SI, Kupferberg HJ, Levy RH, Loiseau P, Perucca E. Progress report on new antiepileptic drugs: a summary of the fourth Eilat conference (EILAT IV). Epilepsy Res 1999; 34(1): 1–41.
   PubMed Web of Science ®Google Scholar
• Welty D, Wang Y, Busch JA, Taylor CP, Vartanian MG, Radulovic LL, et al. Pharmacokinetics (PK) and pharmacodynamics (PD) of CI-1008 (pregabalin) and gabapentin in rats with maximal electroshock. Epilepsia 1997; 38(6): 35–43.
   Google Scholar
• Einarson TR. Drugrelated hospital admissions. Ann Pharmacother 1993; 27(7–8): 8328.
   Web of Science ®Google Scholar
• Roughead EE, Gilbert AL, Primrose JG, Sansom LN. Drugrelated hospital admissions: a review of Australian studies published 1988–1996. Med J Aust 1998; 168(8): 4058.
   Web of Science ®Google Scholar
• Miller RR. Hospital admissions due to adverse drug reactions: a report from the Boston Collaborative Drug Surveillance Program. Arch Intern Med 1974; 134(2): 219–23.
   Google Scholar
• Smith JW, Seidl LG, Cluff LE. Studies on the epidemiology of adverse drug reactions, V: clinical factors influencing susceptibility. Ann Intern Med 1966; 65(4): 629–40.
   Web of Science ®Google Scholar
• Naranjo CA, Busto U, Sellers EM, Sandor P, Ruiz I, Roberts EA. A method for estimating the probability of adverese drug reactions. Clin Pharmacol Ther 1981; 30(2): 239–45.
   PubMed Web of Science ®Google Scholar
• Vartanian MG, Radulovic LL, Kinsora JJ, Serpa KA, Vergnes M, Bertramet E, et al. Activity profile of pregabalin in rodent models of epilepsy and ataxia. Epilepsy Res 2006; 68(3): 189–205.
   PubMed Web of Science ®Google Scholar
• Taylor CP, Angelotti T, Fauman E. Pharmacology and mechanism of action of pregabalin: the calcium channel alpha2-delta (alpha2-delta) subunit as a target for antiepileptic drug discovery. Epilepsy Res 2007; 73(2): 137–50.
   PubMed Web of Science ®Google Scholar
• Dooley DJ, Donovan CM, Meder WP, Whetzel SZ. Preferential action of gabapentin and pregabalin at P/Q-type voltage-sensitive calcium channels: inhibition of K+-evoked [3H]-norepinephrine release from rat neocortical slices. Synapse 2002; 45(3): 171–90.
   Web of Science ®Google Scholar
• Partridge B, Chaplan S, Sakamoto E, Yaksh T. Characterization of the effects of gabapentin and 3-isobutyl-aminobutyric acid on substance P-induced thermal hyperalgesia. Anesthesiology 1998; 88(1): 196–205.
   Web of Science ®Google Scholar
• Field MJ, Holloman EF, McCleary S, Hughes J, Singh L. Evaluation of gabapentin and S-3-isobutylgaba in a rat model of postoperative pain. J Pharmacol Exp Ther 1997; 282(3): 1242–46.
   PubMed Web of Science ®Google Scholar
• Houghton AK, Lu Y, Westlund KN. S-3-Isobutylgaba and its stereoisomer reduces the amount of inflammation and hyperalgesia in an acute arthritis model in the rat. J Pharmacol Exp Ther 1998; 285(2): 533–8.
   Web of Science ®Google Scholar
• Tonyukuk Gedik V, Demir Ö. Peripheric Diabetic Neuropathy. Turkiye Klinikleri J Endocrine-Special Topics 2008; 1(1): 101–6.
   Google Scholar
• Ben-Menachem E. Pregabalin pharmacology and its relevance to clinical practice. Epilepsia 2004; 45(suppl 6): 13–8.
   PubMed Web of Science ®Google Scholar
• Piyapolrungroj N, Li C, Bockbrader H, Liu G, Fleisher D. Mucosal uptake of gabapentin (neurontin) vs. pregabalin in the small intestine. Pharm Res 2001; 18(8): 1126–30.
   PubMed Web of Science ®Google Scholar
• Brodie MJ, Wilson EA, Wesche DL, Alvey CW, Randinitis EJ, Posvar EL. Pregabalin drug interaction studies: lack of effect on the pharmacokinetics of carbamazepine, phenytoin, lamotrigine, and valproate in patients with partial epilepsy. Epilepsia 2005; 46(9): 1407–13.
   PubMed Web of Science ®Google Scholar
• Perucca E. Clinically relevant drug interactions with antiepileptic drugs. Br J Clin Pharmacol 2006; 61(3): 246–55.
   PubMed Web of Science ®Google Scholar
• Moore RA, Straube S, Wiffen PJ, Derry S, McQuay HJ. Pregabalin for acute and chronic pain in adults. Cochrane Database Syst Rev 2009; 8(3): 70–6.
   Google Scholar
• French JA, Kugler AR, Robbins JL, Knapp LE, Garofalo EA. Doseresponse trial of pregabalin adjunctive therapy in patients with partial seizures. Neurology 2003; 60(10): 1631–7.
   PubMed Web of Science ®Google Scholar
• Arroyo S, Anhut H, Kugler AR, Lee CM, Lloyd E, Knapp LE, et al. Pregabalin add-on treatment: a randomized, double-blind, placebo-controlled, dose-response study in adults with partial seizures. Epilepsia 2004; 45(1): 20–7.
   PubMed Web of Science ®Google Scholar
• Gil-Nagel A, Zaccara G, Baldinetti F, Leon T. Add-on treatment with pregabalin for partial seizures with or without generalisation: Pooled data analysis of four randomised placebo-controlled trials. Seizure 2009; 18(10): 184–92.
   Web of Science ®Google Scholar
• Beydoun A, Uthman BM, Kugler AR, Greiner MJ, Knapp LE, Garofalo EA. Safety and efficacy of two pregabalin regimens for add-on treatment of partial epilepsy. Neurology 2005; 64(3): 475–80.
   PubMed Web of Science ®Google Scholar
• Kamel JT, D'Souza WJ, Cook MJ. Severe and disabling constipation: an adverse effect of pregabalin. Epilepsia 2010; 51(6): 1094–6.
   Web of Science ®Google Scholar
• Freynhagen R, Grond S, Schupfer G, Hagebeuker A, Schmelz M, Ziegler D, et al. Efficacy and safety of pregabalin in treatment refractory patients with various neuropathic pain entities in clinical routine. Int J Clin Pract 2007; 61(12): 1989–96.
   Web of Science ®Google Scholar
• Pålsson A, Schultz L, Al-Omar N. Pregabalin (Lyrica) prescription must be cost-effective. Lakartidningen. 2010; 107(11): 773–774.
   Google Scholar
• Huppertz HJ, Feuerstein TJ, Schulze-Bonhage A. Myoclonus in epilepsy patients with anticonvulsive add-on therapy with pregabalin. Epilepsia 2001; 42(6): 790–2.
   PubMed Web of Science ®Google Scholar